Table 2.

Prevalence of BRAFMT status stratified for MMR status, and MMR status stratified for BRAF status in mCRC patients subdivided by study

BRAFMTBRAFWTdMMRpMMR
dMMRpMMRTotaldMMRpMMRTotalBRAFMTBRAFWTTotalBRAFMTBRAFWTTotal
CAIRO12 (48.0%)13 (52.0%)256 (2.0%)291 (98.0%)29712 (66.7%)6 (33.3%)1813 (4.3%)291 (95.7%)304
CAIRO212 (26.7%)33 (73.3%)4517 (3.6%)454 (96.4%)47112 (41.4%)17 (58.6%)2933 (6.8%)454 (93.2%)487
COIN20 (16.7%)100 (83.3%)12045 (3.4%)1,296 (96.6%)1,34120 (30.8%)45 (69.2%)65100 (7.2%)1,296 (92.8%)1,396
FOCUS9 (15.0%)51 (85.0%)6032 (4.5%)672 (95.5%)7049 (22.0%)32 (78.0%)4151 (7.1%)672 (92.9%)723
Pooled dataset53 (21.2%)197 (78.8%)250100 (3.6%)2,713 (96.4%)2,81353 (34.6%)100 (65.4%)153197 (6.8%)2,713 (93.2%)2,910
P0.0020.2390.0070.330

NOTE: Statistically significant results are set in bold. P values represent heterogeneity between the four studies.

Abbreviations: mt, mutant tumors; wt, wild-type tumors.